Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Ramucirumab Monotherapy in Japanese Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma After Platinum or Fluoropyrimidine Therapy
jRCT2080222292Phase 2
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Eli Lilly and Company.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080222292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222292.